dc.contributor.author | Elkashab, Magdy | |
dc.contributor.author | Marcellin, Patrick | |
dc.contributor.author | Ahn, Sang Hoon | |
dc.contributor.author | Ma, Xiaoli | |
dc.contributor.author | Caruntu, Florin A. | |
dc.contributor.author | Tak, Won Young | |
dc.contributor.author | Chuang, Wan-Long | |
dc.contributor.author | Mehta, Rajiv | |
dc.contributor.author | Petersen, Joerg | |
dc.contributor.author | Martins, Eduardo B. | |
dc.contributor.author | Dinh, Phillip | |
dc.contributor.author | Corsa, Amoreena C. | |
dc.contributor.author | Charuworn, Prista | |
dc.contributor.author | Subramanian, Mani | |
dc.contributor.author | McHutchison, John G. | |
dc.contributor.author | Buti, Maria | |
dc.contributor.author | Gaeta, Giovanni B. | |
dc.contributor.author | Papatheodoridis, George V. | |
dc.contributor.author | Flisiak, Robert | |
dc.contributor.author | Chan, Henry Lik-Yuen | |
dc.contributor.author | Tabak, Fehmi | |
dc.date.accessioned | 2021-03-03T09:42:48Z | |
dc.date.available | 2021-03-03T09:42:48Z | |
dc.identifier.citation | Marcellin P., Ahn S. H. , Ma X., Caruntu F. A. , Tak W. Y. , Elkashab M., Chuang W., Tabak F., Mehta R., Petersen J., et al., "HBsAg Loss with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic Hepatitis B (CHB): Results of a Global Randomized Controlled Trial", 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, Amerika Birleşik Devletleri, 7 - 11 Kasım 2014, cilt.60 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1e84460e-9404-4c3c-8bfc-e3a0a8f9d0d2 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/25669 | |
dc.language.iso | eng | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.title | HBsAg Loss with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic Hepatitis B (CHB): Results of a Global Randomized Controlled Trial | |
dc.type | Bildiri | |
dc.contributor.department | Assistance Publique Hopitaux Paris (APHP) , , | |
dc.identifier.volume | 60 | |
dc.contributor.firstauthorID | 143589 | |